CL2007003226A1 - Compuestos derivados de piridinona; composicion farmaceutica; y uso para tratar el cancer. - Google Patents
Compuestos derivados de piridinona; composicion farmaceutica; y uso para tratar el cancer.Info
- Publication number
- CL2007003226A1 CL2007003226A1 CL200703226A CL2007003226A CL2007003226A1 CL 2007003226 A1 CL2007003226 A1 CL 2007003226A1 CL 200703226 A CL200703226 A CL 200703226A CL 2007003226 A CL2007003226 A CL 2007003226A CL 2007003226 A1 CL2007003226 A1 CL 2007003226A1
- Authority
- CL
- Chile
- Prior art keywords
- piridinona
- pharmaceutical composition
- treat cancer
- compounds derived
- derived
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85754006P | 2006-11-08 | 2006-11-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2007003226A1 true CL2007003226A1 (es) | 2008-02-08 |
Family
ID=39048786
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL200703226A CL2007003226A1 (es) | 2006-11-08 | 2007-11-08 | Compuestos derivados de piridinona; composicion farmaceutica; y uso para tratar el cancer. |
Country Status (21)
Country | Link |
---|---|
US (2) | US7851489B2 (es) |
EP (1) | EP2089364B1 (es) |
JP (1) | JP5276005B2 (es) |
KR (1) | KR101390076B1 (es) |
CN (1) | CN101535264B (es) |
AR (1) | AR063628A1 (es) |
AU (1) | AU2007317296B2 (es) |
CA (1) | CA2669266C (es) |
CL (1) | CL2007003226A1 (es) |
DK (1) | DK2089364T3 (es) |
ES (1) | ES2424851T3 (es) |
HK (1) | HK1131608A1 (es) |
HR (1) | HRP20130626T1 (es) |
MX (1) | MX2009004699A (es) |
NO (1) | NO342395B1 (es) |
PE (1) | PE20081490A1 (es) |
PL (1) | PL2089364T3 (es) |
PT (1) | PT2089364E (es) |
SI (1) | SI2089364T1 (es) |
TW (1) | TWI409259B (es) |
WO (1) | WO2008058229A1 (es) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009094427A1 (en) * | 2008-01-23 | 2009-07-30 | Bristol-Myers Squibb Company | 4-pyridinone compounds and their use for cancer |
CA2726588C (en) | 2008-06-03 | 2019-04-16 | Karl Kossen | Compounds and methods for treating inflammatory and fibrotic disorders |
AU2011248441A1 (en) | 2010-04-29 | 2012-12-20 | Deciphera Pharmaceuticals, Llc | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activites |
KR101897302B1 (ko) * | 2010-04-30 | 2018-09-11 | 브리스톨-마이어스 스큅 컴퍼니 | N-(4-(2-아미노-3-클로로피리딘-4-일옥시)-3-플루오로페닐)-4-에톡시-1-(4-플루오로페닐)-2-옥소-1,2-디히드로피리딘-3-카르복스아미드를 포함하는 제약 조성물 |
CN102241625B (zh) * | 2010-05-13 | 2014-10-29 | 中南大学 | 1-(取代芳基)-5-((取代芳胺基)甲基)吡啶-2(1h)酮化合物、制备方法及其用途 |
CN102070518B (zh) * | 2011-01-24 | 2012-05-02 | 江苏先声药物研究有限公司 | 取代吡啶及氮杂吲哚衍生物的合成 |
KR20140007954A (ko) | 2011-06-10 | 2014-01-20 | 메르크 파텐트 게엠베하 | Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물의 조성물 및 제조방법 |
KR20140097402A (ko) | 2011-11-22 | 2014-08-06 | 데시페라 파마슈티칼스, 엘엘씨. | 항암 및 항증식 활성을 나타내는 피리돈 아미드 및 유사체 |
CA2876246C (en) | 2012-07-28 | 2019-05-07 | Calitor Sciences, Llc | Substituted pyrazolone compounds and methods of use |
US8975282B2 (en) | 2012-07-28 | 2015-03-10 | Sunshine Lake Pharma Co., Ltd. | Substituted pyrazolone compounds and methods of use |
AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
CN110452216B (zh) | 2014-04-02 | 2022-08-26 | 英特穆恩公司 | 抗纤维化吡啶酮类 |
ES2928164T3 (es) | 2015-10-19 | 2022-11-15 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
TWI763641B (zh) | 2015-11-19 | 2022-05-11 | 美商英塞特公司 | 作為免疫調節劑之雜環化合物 |
MA55194A (fr) | 2015-12-22 | 2022-05-04 | Incyte Corp | Composés hétérocycliques en tant qu'immunomodulateurs |
WO2017192961A1 (en) | 2016-05-06 | 2017-11-09 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
MA45116A (fr) | 2016-05-26 | 2021-06-02 | Incyte Corp | Composés hétérocycliques comme immunomodulateurs |
UA125391C2 (uk) | 2016-06-20 | 2022-03-02 | Інсайт Корпорейшн | Гетероциклічні сполуки як імуномодулятори |
US20180016260A1 (en) * | 2016-07-14 | 2018-01-18 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
MA46045A (fr) | 2016-08-29 | 2021-04-28 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
CA3044366A1 (en) * | 2016-12-19 | 2018-06-28 | Novartis Ag | New picolinic acid derivatives and their use as intermediates |
WO2018119236A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
ES2934230T3 (es) | 2016-12-22 | 2023-02-20 | Incyte Corp | Derivados de benzooxazol como inmunomoduladores |
WO2018136010A1 (en) | 2017-01-20 | 2018-07-26 | Aslan Pharmaceuticals Pte Ltd | Combination therapy |
WO2018136009A1 (en) | 2017-01-20 | 2018-07-26 | Aslan Pharmaceuticals Pte Ltd | Combination therapy |
EP3589286B1 (en) | 2017-03-02 | 2022-08-03 | ASLAN Pharmaceuticals Pte Ltd | Dhodh inhibitor for treating haematological cancer |
CN108623568B (zh) * | 2017-03-21 | 2022-04-19 | 南京汇诚制药有限公司 | 9,10二氢菲类丙型肝炎病毒抑制剂的盐型及其制备 |
WO2018222135A1 (en) | 2017-06-02 | 2018-12-06 | Aslan Pharmaceuticals Pte Ltd | Cancer therapy |
WO2018222134A1 (en) | 2017-06-02 | 2018-12-06 | Aslan Pharmaceuticals Pte Ltd | Cancer therapy |
WO2019083455A1 (en) | 2017-10-25 | 2019-05-02 | Aslan Pharmaceuticals Pte Ltd | VARLITINIB FOR USE IN THE TREATMENT OF CANCER IN A PATIENT IDENTIFIED AS PRESENTING HER1, HER2 AND / OR HER3-ACTIVATED HERC-RECEPTOR CANCER CELLS |
WO2019083458A1 (en) | 2017-10-25 | 2019-05-02 | Aslan Pharmaceuticals Pte Ltd | VARLITINIB FOR THE TREATMENT OF CANCER TO REDUCE HYPOXIA |
WO2019083457A1 (en) | 2017-10-25 | 2019-05-02 | Aslan Pharmaceuticals Pte Ltd | VARLITINIB FOR USE IN THE TREATMENT OF CANCER IN A PATIENT IDENTIFIED AS MUTATION OF THE BETA-CATENIN PATHWAY |
WO2019083456A1 (en) | 2017-10-25 | 2019-05-02 | Aslan Pharmaceuticals Pte Ltd | VARLITINIB FOR USE IN THE TREATMENT OF CANCER FOR NORMALIZING ANGIOGENESIS IN A CANCER MASS |
US11623923B2 (en) | 2017-11-24 | 2023-04-11 | Medshine Discovery, Inc. | Uracil compound as c-MET/AXL inhibitor |
AU2019237715B2 (en) | 2018-03-08 | 2021-01-28 | Wellmarker Bio Co., Ltd. | Thienopyridine derivatives and pharmaceutical composition comprising same |
MD3790877T2 (ro) | 2018-05-11 | 2023-08-31 | Incyte Corp | Derivați de tetrahidro-imidazo[4,5-c]piridină în calitate de imunomodulatori PD-L1 |
US20210379070A1 (en) | 2018-10-09 | 2021-12-09 | Aslan Pharmaceuticals Pte Ltd | Malonate salt of varlitinib |
JP2022505272A (ja) * | 2018-10-19 | 2022-01-14 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | がん治療のためのトポイソメラーゼii触媒阻害剤化合物による治療、方法、及び使用 |
US20220119425A1 (en) * | 2019-01-15 | 2022-04-21 | The Translational Genomics Research Institute | Phosphonate conjugates and uses thereof |
CN114206883A (zh) | 2019-08-02 | 2022-03-18 | 伟迈可生物有限公司 | 氧代吡啶稠环衍生物及包含该衍生物的药物组合物 |
WO2021030162A1 (en) | 2019-08-09 | 2021-02-18 | Incyte Corporation | Salts of a pd-1/pd-l1 inhibitor |
JP2022554042A (ja) | 2019-09-06 | 2022-12-28 | ウェルマーカー・バイオ・カンパニー・リミテッド | バイオマーカー型治療用組成物 |
AU2020385113A1 (en) | 2019-11-11 | 2022-05-19 | Incyte Corporation | Salts and crystalline forms of a PD-1/PD-L1 inhibitor |
EP4129295A4 (en) | 2020-02-06 | 2023-12-27 | Wellmarker Bio Co., Ltd. | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCERS ASSOCIATED WITH A KRAS MUTATION |
KR20210111711A (ko) | 2020-03-03 | 2021-09-13 | 웰마커바이오 주식회사 | Kras 돌연변이 및 활성화된 ron이 존재하는 암의 예방 또는 치료용 약학 조성물 |
US20230202992A1 (en) | 2020-05-18 | 2023-06-29 | Wellmarker Bio Co., Ltd. | Pharmaceutical composition for preventing or treating small-cell lung cancer associated with ron mutants and method using same |
US20230241073A1 (en) | 2020-05-18 | 2023-08-03 | Wellmarker Bio Co., Ltd. | Pharmaceutical composition for preventing or treating non-small cell lung cancer associated with ron mutantation, and method using same |
WO2021235813A1 (ko) | 2020-05-18 | 2021-11-25 | 웰마커바이오 주식회사 | Ron 돌연변이와 관련된 췌장암 예방 또는 치료용 약학 조성물 및 이를 이용한 방법 |
US11760756B2 (en) | 2020-11-06 | 2023-09-19 | Incyte Corporation | Crystalline form of a PD-1/PD-L1 inhibitor |
US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
CA3200844A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof |
KR20220170766A (ko) * | 2021-06-22 | 2022-12-30 | 주식회사 엘지화학 | 단백질 키나아제 억제제로서의 신규한 화합물 |
US20230257364A1 (en) * | 2022-02-16 | 2023-08-17 | Cmg Pharmaceutical Co., Ltd. | Pyridazinone-based compounds as axl, c-met, and mer inhibitors and methods of use thereof |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0430885A3 (en) | 1989-12-01 | 1991-11-06 | Ciba-Geigy Ag | Anthelmintical compounds |
WO1997017329A1 (fr) | 1995-11-07 | 1997-05-15 | Kirin Beer Kabushiki Kaisha | Derives de quinoline et derives de quinazoline inhibant l'autophosphorylation d'un recepteur de facteur de croissance originaire de plaquettes, et compositions pharmaceutiques les contenant |
AU4692399A (en) | 1998-06-17 | 2000-01-05 | Du Pont Pharmaceuticals Company | Cyclic hydroxamic acids as metalloproteinase inhibitors |
US6355660B1 (en) | 1999-07-20 | 2002-03-12 | Dow Agrosciences Llc | Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation |
BR0012615A (pt) | 1999-07-20 | 2004-03-30 | Dow Agrosciences Llc | Amidas aromáticas heterocìclicas fungicidas e suas composições, métodos de uso e preparação |
CA2384291A1 (en) | 1999-09-21 | 2001-03-29 | Astrazeneca Ab | Quinazoline derivatives and their use as pharmaceuticals |
FR2812633A1 (fr) | 2000-08-04 | 2002-02-08 | Aventis Cropscience Sa | Derives de phenyl(thio)urees et phenyl(thio)carbamates fongicides |
SE0102384D0 (sv) | 2001-07-03 | 2001-07-03 | Pharmacia Ab | New compounds |
AU2002344567A1 (en) | 2001-11-28 | 2003-06-10 | Daiso Co., Ltd. | Heterocyclic amide compounds as apolipoprotein b inhibitors |
SE0302487D0 (sv) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
JP4829506B2 (ja) | 2004-02-17 | 2011-12-07 | 石原産業株式会社 | チオアミド系化合物又はその塩、並びにそれらを含有するサイトカイン産生抑制剤 |
US7459562B2 (en) * | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
WO2005113494A2 (en) | 2004-05-07 | 2005-12-01 | Amgen Inc. | Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer |
US7439246B2 (en) | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
US7173031B2 (en) | 2004-06-28 | 2007-02-06 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
US7432373B2 (en) | 2004-06-28 | 2008-10-07 | Bristol-Meyers Squibb Company | Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors |
JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
WO2007033196A1 (en) | 2005-09-14 | 2007-03-22 | Bristol-Myers Squibb Company | Met kinase inhibitors |
US7880004B2 (en) | 2005-09-15 | 2011-02-01 | Bristol-Myers Squibb Company | Met kinase inhibitors |
US7348325B2 (en) | 2005-11-30 | 2008-03-25 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
-
2007
- 2007-11-08 CA CA2669266A patent/CA2669266C/en active Active
- 2007-11-08 MX MX2009004699A patent/MX2009004699A/es active IP Right Grant
- 2007-11-08 WO PCT/US2007/084047 patent/WO2008058229A1/en active Application Filing
- 2007-11-08 KR KR1020097009449A patent/KR101390076B1/ko active IP Right Grant
- 2007-11-08 EP EP07844974.1A patent/EP2089364B1/en active Active
- 2007-11-08 CN CN2007800414202A patent/CN101535264B/zh active Active
- 2007-11-08 PT PT78449741T patent/PT2089364E/pt unknown
- 2007-11-08 TW TW096142253A patent/TWI409259B/zh active
- 2007-11-08 CL CL200703226A patent/CL2007003226A1/es unknown
- 2007-11-08 ES ES07844974T patent/ES2424851T3/es active Active
- 2007-11-08 AR ARP070104987A patent/AR063628A1/es active Pending
- 2007-11-08 AU AU2007317296A patent/AU2007317296B2/en active Active
- 2007-11-08 PE PE2007001538A patent/PE20081490A1/es active IP Right Grant
- 2007-11-08 SI SI200731303T patent/SI2089364T1/sl unknown
- 2007-11-08 PL PL07844974T patent/PL2089364T3/pl unknown
- 2007-11-08 JP JP2009536476A patent/JP5276005B2/ja active Active
- 2007-11-08 DK DK07844974.1T patent/DK2089364T3/da active
- 2007-11-08 US US11/936,984 patent/US7851489B2/en active Active
-
2009
- 2009-04-22 NO NO20091605A patent/NO342395B1/no unknown
- 2009-11-02 HK HK09110170.2A patent/HK1131608A1/xx unknown
-
2010
- 2010-11-08 US US12/941,419 patent/US8536200B2/en active Active
-
2013
- 2013-07-03 HR HRP20130626TT patent/HRP20130626T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
HRP20130626T1 (en) | 2013-08-31 |
KR101390076B1 (ko) | 2014-04-29 |
NO20091605L (no) | 2009-05-27 |
DK2089364T3 (da) | 2013-09-02 |
PL2089364T3 (pl) | 2013-11-29 |
AR063628A1 (es) | 2009-02-04 |
US20110052583A1 (en) | 2011-03-03 |
TWI409259B (zh) | 2013-09-21 |
CA2669266A1 (en) | 2008-05-15 |
ES2424851T3 (es) | 2013-10-09 |
AU2007317296B2 (en) | 2012-07-05 |
MX2009004699A (es) | 2009-05-15 |
US8536200B2 (en) | 2013-09-17 |
WO2008058229A1 (en) | 2008-05-15 |
CN101535264B (zh) | 2012-11-28 |
PE20081490A1 (es) | 2008-10-30 |
SI2089364T1 (sl) | 2013-10-30 |
US7851489B2 (en) | 2010-12-14 |
CN101535264A (zh) | 2009-09-16 |
PT2089364E (pt) | 2013-08-26 |
TW200829564A (en) | 2008-07-16 |
EP2089364A1 (en) | 2009-08-19 |
NO342395B1 (no) | 2018-05-14 |
KR20090096423A (ko) | 2009-09-10 |
JP5276005B2 (ja) | 2013-08-28 |
US20080114033A1 (en) | 2008-05-15 |
CA2669266C (en) | 2014-04-29 |
HK1131608A1 (en) | 2010-01-29 |
EP2089364B1 (en) | 2013-06-12 |
AU2007317296A1 (en) | 2008-05-15 |
JP2010509362A (ja) | 2010-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2007003226A1 (es) | Compuestos derivados de piridinona; composicion farmaceutica; y uso para tratar el cancer. | |
CL2007003774A1 (es) | Compuestos derivados de quinazolina sustituidos, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, aterosclerosis y artritis. | |
CL2008002319A1 (es) | Compuestos derivados de pirrolopirimidina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer. | |
CL2008000046A1 (es) | Compuestos derivados de 2-(4-piperidin-3-il-fenil)-7-amido-2,7a-dihidro-1h-indazol; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar o prevenir el cancer, enfermedades inflamatorias, lesiones por reperfusion, afeccione | |
CL2008000197A1 (es) | Compuestos derivados de 2,4-diamino pirimidina, inhibidores de antranilamida de cinasa aurora; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer. | |
CL2007003138A1 (es) | Compuestos derivados de anilinopiperazina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. | |
CL2007000161A1 (es) | Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer. | |
CL2008001076A1 (es) | Compuestos derivados de sulfonamida; composicion farmaceutica; y uso en el tratamiento del cancer. | |
CL2007002316A1 (es) | Compuestos derivados de pirimidina, inhibidores de pi3k; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en enfermedades proliferativas como cancer. | |
CL2007001630A1 (es) | Compuestos derivados de pirrolidinamida; composicion farmaceutica; y uso para el tratamiento de la hepatitis c. | |
CL2008000403A1 (es) | Compuestos derivados de pentafluorotiobenzamido-acetonitrilo; composicion farmaceutica; y uso para tratar una infestacion por parasitos. | |
CL2008000754A1 (es) | Compuesto derivado de heterociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso para tratar cancer y trastornos hiperproliferativos. | |
BRPI0819218A2 (pt) | Métodos, estojos e composições para administração de compostos farmacêuticos | |
CL2007000806A1 (es) | Compuestos derivados de heteropentaciclos sustituidos; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento del cancer. | |
CL2008001633A1 (es) | Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer. | |
CL2007002377A1 (es) | Compuestos derivados de quinazolina; procedimiento de preparacion; composicion farmaceutica; y su uso como anticancerigeno. | |
BRPI0922475A2 (pt) | composto, composição farmacêutica , método para tratar câncer, e, uso de um composto. | |
BRPI0821115A2 (pt) | Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto | |
BRPI0815709A2 (pt) | composro, composição farmacêutica, e, uso de um composto. | |
CL2007002790A1 (es) | Compuestos derivados de 1h-indol y 1h-bencimidazol; composicion farmaceutica; y uso para el tratamiento de hipogonadismo, osteoporosis y cancer de prostata entre otros. | |
CL2008002893A1 (es) | Compuestos derivados de n-fenil-(piridin-3-il) acetamida sustituidas; composicion farmaceutica; procedimiento de preparacion; y su uso para prevenir o tratar el cancer. | |
CL2007003212A1 (es) | Compuestos derivados de imidazopirazinas, inhibidores de proteina quinasa; composicion farmaceutica que los comprende; y su uso para tratar cancer. | |
CL2007003244A1 (es) | Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. | |
CL2007002920A1 (es) | Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos. | |
CL2008002295A1 (es) | Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c. |